HOME / CONTACT US
繁體版 / 简体版
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate presentation
    • Corporate governance
    • Financials
    • 企業社會責任
    • 股東專區
    • 向股東報告
    • 財務資訊
    • Investor faqs
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CAREERS
    • Careers
    • Join us
  • ABOUT COMPANY
    • History
    • Team
    • Collabration
    • Nanchou Plant
  • SCIENCE
    • Pipeline & Therapeutic area
    • ON101
    • OB318
    • FB825
    • FB704A
    • FB918
    • SNS01
    • Technology
  • INVESTOR
    • Corporate Governance
      • Governance Structure Shareholding Structure Board of Directors Audit Committee Compensation Committee Internal Audit Major Internal Policies
    • Financials
      • Financial Report Stock Quotes
    • Investor FAQs
      • CONTACT US FAQs(category)
    • Corporate Presentation
      • Events and Presentations
    • 關於合一
      • History Team Collabration Nanchou Plant
    • SCIENCE
      • Pipeline & Therapeutic area ON101 OB318 FB825 FB704A FB918 SNS01 Technology
    • 人力資源
      • Careers Join us
  • NEWS
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
  • CAREERS
    • Careers
    • Join us
  • CONTACT US
  • 繁體版
  • 简体版
 
 
NEWS
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017

NEWS

 

Title Date
Oneness Biotech invited speaker at 2018 Asia Pacific Biotech Investment Forum hosted by Diamond Biofund Inc. 2018-11-12
Oneness Biotech receives license payment by Microbio (Shanghai) for obtaining the right of diabetic foot ulcer new drug, ON101 in China, Hong Kong and Macao. 2018-11-05
Oneness Biotech has been invited to present the clinical data of ON101 at the International Diabetes Federation, IDF) conference. 2018-10-22
Oneness Biotech invited to the 16th Annual Global Healthcare Conference by Morgan Stanley. 2018-09-05
Oneness Biotech submitted the plant-derived new drug application of ON101 (Diabetic foot ulcer drug) to TFDA 2018-05-14
US FDA approved the second Phase III clinical studies for the new drug from Oneness Biotech 2018-03-04


Copyright © Oneness Biotech Co., Ltd. All Rights Reserved.